The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Third Point Takes an Activist Stance on Intel, US Stocks End Lower Tuesday With Direct Payment Uncertainty, Orexo announces new US patent for ZUBSOLV®, NeuroRx and Relief Conclude Enrollment in their Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure, Announcement of change in the total number of votes in AB SKF, Clean Power Capital Announces Appointment of Amp Energy Founder & CEO Dave Rogers to the PowerTap Advisory Board, John Rogers Says Market Valuations Are Reminiscent of the 1970s, Warren Buffett Calls on Congress to Help Small Businesses, Bill Nygren Sees Value in Ally Financial, Capital One as Vaccines Spark a Return to Normalcy, Mohnish Pabrai Shares Insights on Identifying 10 to 100-Baggers - Part 3, Warren Buffett: Why IPOs Can Be Painful for Investors, Aratana Therapeutics Granted FDA Approval of NOCITA® (bupivacaine liposome injectable suspension) 10 mL Vial, Aratana Therapeutics Reports Voting Results from 2019 Annual Meeting of Stockholders, Aratana Therapeutics Reports First Quarter 2019 Financial Results, Aratana Therapeutics to Present at Stifel 2019 Dental & Veterinary Conference. View original content to download multimedia:http://www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html. Aratana Therapeutics Inc is a pet therapeutics company. LEAWOOD, Kan., July 16, 2019 — Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting results for the three proposals considered and voted upon by its stockholders at its Special Meeting on July 16, 2019. A DIY Guide on How to Invest Using Guru Strategies, http://www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html. announces that it […] Rewire fixed ideas to ease personal torment over euthanasia, Rule out common illnesses before testing for COVID-19, AVMA says, Feline respiratory health “static” amid pandemic, FDA loosens telemedicine regulations amid COVID-19 pandemic. Elanco and Aratana Therapeutics finalize deal to merge The company will form a new commercial team dedicated to the veterinary specialty business July 18, 2019 Elanco Animal Health has acquired Aratana Therapeutics. The closing of the merger will take place no later than two business days following when the last of the closing conditions of the merger have been satisfied or waived. © 2004-2020 GuruFocus.com, LLC. The company's portfolio consists of therapeutic candidates such as small … LEAWOOD, Kan., July 16, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. , a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats,... | November 25, 2020 Aratana Therapeutics' Stockholders Adopt Merger Agreement with Elanco Animal Health PR Newswire Tue, Jul. Approximately 73% (35,769,162) of the Company's outstanding common stock as of the June 14, 2019 record date was present in person or represented by proxy at the Special Meeting and of the shares voted, approximately 99% voted in favor of adopting the merger proposal. Further, Aratana’s research and development pipeline will contribute to Elanco’s efforts to sustain the introduction of novel and innovative companion animal therapeutics. These factors include risks and uncertainties related to, among other things: (1) the inability to close the merger in a timely manner; (2) the inability to complete the merger due to the failure to obtain Aratana stockholder adoption of the merger agreement or the failure to satisfy other conditions to completion of the merger, including required regulatory approvals; (3) the failure of the transaction to close for any other reason; (4) the possibility that the integration of Aratana's business and operations with those of Elanco may be more difficult and/or take longer than anticipated, may be more costly than anticipated and may have unanticipated adverse results relating to Aratana's or Elanco's existing businesses; (5) the effect of the announcement of the transaction on Elanco's, Aratana's or the combined company's respective business relationships, operating results and business generally; (6) diversion of management's attention from ongoing business concerns; and (7) other factors that may affect future results of the combined company described in the section entitled "Risk Factors" in the proxy statement/prospectus to be mailed to Aratana's stockholders and in Elanco's and Aratana's respective filings with the U.S. Securities and Exchange Commission ("SEC") that are available on the SEC's web site located at www.sec.gov, including the sections entitled "Risk Factors" in Elanco's and Aratana's Annual Reports on Form 10-K for the fiscal year ended December 31, 2018. A Form 8-K disclosing the full voting results will be filed with the Securities and Exchange Commission on July 16, 2019. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. The closing of the merger will take place no later than two business days following when the last of the closing conditions of the merger have been satisfied or waived.